Skip to main content

Advertisement

SpringerLink
Log in

Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin)

  • PRECLINICAL STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

We constructed a replication-competent oncolytic adenovirus, OBP-301 (Telomelysin), in which human telomerase reverse transcriptase (hTERT) promoter drives E1 genes. OBP-301 is currently being used in a phase-I clinical trial for various types of tumors. Under such conditions, anti-adenoviral agents should be available for safety use against OBP-301 since any adenoviral viremia could cause severe adverse effects. Cidofovir (CDV) is an acyclic nucleoside phosphonate that has a broad antiviral activity against DNA viruses. Here, we examined the antiviral effects of CDV against OBP-301. The in vitro cytopathic effects of OBP-301 were suppressed by CDV. Moreover, CDV decreased the adenoviral E1A gene copy number after OBP-301 infection. These results suggest that CDV is a potentially useful antiviral agent for OBP-301.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kirn D, Martuza RL, Zwiebel J (2001) Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 7:781–787. doi:10.1038/89901

    Article  CAS  PubMed  Google Scholar 

  2. Kirn D (2000) Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 19:6660–6669. doi:10.1038/sj.onc.1204094

    Article  CAS  PubMed  Google Scholar 

  3. Chu RL, Post DE, Khuri FR, Van Meir EG (2004) Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 10:5299–5312. doi:10.1158/1078-0432.CCR-0349-03

    Article  CAS  PubMed  Google Scholar 

  4. Davis JJ, Fang B (2005) Oncolytic virotherapy for cancer treatment: challenges and solutions. J Gene Med 7:1380–1389. doi:10.1002/jgm.800

    Article  CAS  PubMed  Google Scholar 

  5. Nakamura TM, Morfin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J et al (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955–959. doi:10.1126/science.277.5328.955

    Article  CAS  PubMed  Google Scholar 

  6. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015. doi:10.1126/science.7605428

    Article  CAS  PubMed  Google Scholar 

  7. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F et al (2004) Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 10:285–292. doi:10.1158/1078-0432.CCR-1075-3

    Article  CAS  PubMed  Google Scholar 

  8. Taki M, Kagawa S, Nishizaki M, Mizuguchi H, Hayakawa T, Kyo S et al (2005) Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 (Telomelysin-RGD). Oncogene 24:3130–3140. doi:10.1038/sj.onc.1208460

    Article  CAS  PubMed  Google Scholar 

  9. Hashimoto Y, Watanabe Y, Shirakiya Y, Uno F, Kagawa S, Kawamura H et al (2008) Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci 99:385–390. doi:10.1111/j.1349-7006.2007.00665.x

    Article  CAS  PubMed  Google Scholar 

  10. Gordon YJ, Romanowski E, Araullo-Cruz T, Seaberg L, Erzurum S, Tolman R et al (1991) Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2’¢-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antivir Res 16:11–16. doi:10.1016/0166-3542(91)90054-U

    Article  CAS  PubMed  Google Scholar 

  11. De Clercq E (2003) Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 16:569–596. doi:10.1128/CMR.16.4.569-596.2003

    Article  PubMed  Google Scholar 

  12. Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T, Uno F et al (2006) In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med 12:1213–1219. doi:10.1038/nm1404

    Article  CAS  PubMed  Google Scholar 

  13. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J et al (2002) Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 62:6070–6079

    CAS  PubMed  Google Scholar 

  14. Whitley RJ, Roizman B (2001) Herpes simplex virus infection. Lancet 357:1513–1518. doi:10.1016/S0140-6736(00)04638-9

    Article  CAS  PubMed  Google Scholar 

  15. Biron KK (2006) Antiviral drugs for cytomegalovirus diseases. Antivir Res 71:154–163. doi:10.1016/j.antiviral.2006.05.002

    Article  CAS  PubMed  Google Scholar 

  16. Naesens L, Lenaerts L, Andrei G, Snoeck R, Van Beers D, Holy A et al (2005) Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother 49:1010–1016. doi:10.1128/AAC.49.3.1010-1016.2005

    Article  CAS  PubMed  Google Scholar 

  17. Morfin F, Dupuis-Girod S, Mundweiler S, Falcon D, Carrington D, Sedlacek P et al (2005) In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther 10:225–229

    CAS  PubMed  Google Scholar 

  18. Kinchington PR, Araullo-Cruz T, Vergnes JP, Yates K, Gordon YJ (2002) Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir. Antivir Res 56:73–84. doi:10.1016/S0166-3542(02)00098-0

    Article  CAS  PubMed  Google Scholar 

  19. Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RM, Painter GR et al (2008) Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci U S A 105:7293–7297. doi:10.1073/pnas.0800200105

    Article  CAS  PubMed  Google Scholar 

  20. Gordon YJ, Araullo-Cruz TP, Johnson YF, Romanowski EG, Kinchington PR (1996) Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir. Invest Ophthalmol Vis Sci 37:2774–2778

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncolys BioPharma, Inc., Tokyo, 106-0032, Japan

    Masaaki Ouchi, Hitoshi Kawamura & Yasuo Urata

  2. Center for Gene and Cell Therapy, Okayama University Hospital, Okayama, 700-8558, Japan

    Toshiyoshi Fujiwara

Authors
  1. Masaaki Ouchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hitoshi Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuo Urata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshiyoshi Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshiyoshi Fujiwara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ouchi, M., Kawamura, H., Urata, Y. et al. Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin). Invest New Drugs 27, 241–245 (2009). https://doi.org/10.1007/s10637-008-9169-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-008-9169-5

Keywords

Search

Navigation